| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC1683 |
| Trial ID | NCT03016377 |
| Disease | Acute Lymphoblastic Leukemia | Immune System Disease |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19 CAR-T cells |
| Co-treatment | Rimiducid |
| Generation | 2nd |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL |
| Year | 2018 |
| Country | United States |
| Company sponsor | UNC Lineberger Comprehensive Cancer Center |
| Other ID(s) | LCCC 1541-ATL |
| Cohort 1 | |||||||||||||||
|
|||||||||||||||